Daclatasvir combo gets Breakthrough status

Share this article:

Bristol-Myers Squibb landed a Breakthrough Therapy designation for its daclatasvir + asunaprevir combination to treat genotype 1b hep. C. The regulator granted the designation based on Phase-III clinical data involving the all-oral, two-drug regimen.

If the drug mix sounds familiar, it is: the FDA granted Breakthrough Therapy status in October 2013 to an all-oral combination of daclatasvir, asunaprevir and BMS-791325, which is being studied in non-cirrhotic, treatment-naïve and experienced patients, as well as cirrhotic, treatment naïve and experienced patients.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions